research use only
Cat.No.S1721
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other Rho Inhibitors | NSC 23766 Trihydrochloride CCG-1423 ML141 (CID-2950007) EHop-016 EHT 1864 2HCl ZCL278 MBQ-167 Rhosin hydrochloride CCG-203971 CID44216842 |
|
In vitro |
DMSO
: 54 mg/mL
(194.76 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 277.26 | Formula | C9H7N7O2S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 446-86-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | BW 57-322 | SMILES | CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
Rac1
|
|---|---|
| In vitro |
Azathioprine suppresses the activation of Rac1 target genes such as mitogen-activated protein kinase kinase (MEK), NF-kappaB, and bcl-x(L), leading to a mitochondrial pathway of apoptosis in primary human CD4+ T lymphocytes. This compound thus converts a costimulatory signal into an apoptotic signal by modulating Rac1 activity. This compound-generated 6-Thio-GTP thus prevents the development of an effective immune response via blockade of Vav activity on Rac proteins. This chemical (1 mM) restores ATP levels and arrests cell injury, while culture in glucose-enriched media augments ATP levels and ameliorates cell death. It reduces viability 5-34% at day 1 and 42-92% by day 4. This agent decreases the viability of hepatocytes and induces the following events in primary culture of isolated rat hepatocytes: intracellular reduces glutathione (GSH) depletion, metabolic activity reduction, and lactate dehydrogenase release. Its effect on hepatocytes is associated with swelling and increased oxygen consumption of intact isolated rat liver mitochondria. |
| In vivo |
Azathioprine combined with cyclosporin A and prednisolone has resulted in survival of 14 out of 15 grafts (93%), compared with 11 out of 14 (79%) in the group treated with cyclosporin A alone in mouse-rat brain xenograft. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-07-23)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07616154 | RECRUITING | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2026-09 | PHASE2 |
| NCT07352566 | NOT_YET_RECRUITING | Psoriasis; Atopic Dermatitis |
University of California, San Francisco |
2026-08-01 | PHASE4 |
| NCT05584228 | NOT_YET_RECRUITING | Crohn Disease |
Nantes University Hospital |
2026-10-01 | |
| NCT07659353 | NOT_YET_RECRUITING | Chrohn's Disease |
University Hospital Schleswig-Holstein |
2026-08-01 | PHASE4 |
| NCT02939573 | RECRUITING | Primary Cutaneous Vasculitis; Cutaneous Polyarteritis Nodosa; IgA Vasculitis; Henoch-Schönlein Purpura |
University of Pennsylvania |
2017-01-01 | PHASE2 |
| NCT07619898 | NOT_YET_RECRUITING | Colitis; Hepatitis; Melanoma (Skin Cancer) |
Therakos LLC |
2026-07 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.